RY-103 is under clinical development by Neuracle Science and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase I drugs for Neurodegenerative Diseases have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RY-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RY-103 is under development for the treatment of scarring and cognitive impairment in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS). The drug candidate is a humanized NGDF-antibody which acts by targeting NGDF, a novel neuropeptide secreted by astrocytes. It is administered through intravenous route.
Neuracle Science overview
Neuracle Science is a South Korean biotechnology company that discovers and develops drugs for the treatment of neurological diseases, including parkinson’s, alzheimer’s, degenerative dyskinesia, neurogenic bowel dysfunction, irritable bowel syndrome, amyotrophic lateral sclerosis, neuropathic pain, schizophrenia and depression. Neuracle Science is headquartered in Seoul, South Korea.
For a complete picture of RY-103’s drug-specific PTSR and LoA scores, buy the report here.